ERBB2 and breast cancer: Interestingly, in a recent study of 787 individuals of young adult populations treated with trastuzumab in the adjuvant setting of HER2-positive breast cancer, a drop of > 5% LV EF within the first 3 months of treatment, even with subsequent normalisation of function, was strongly associated with later development of trastuzumab related cardiotoxicity [10].